All In Biotech

Drug Trial Radar · NCT07257627

Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites

An Open-Label, Randomized, Three-Period Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Single-Dose THDB0206 Injection at Different Injection Sites in Healthy Chinese Adults

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Apr 17, 2024

Primary completion

Dec 2, 2024

Study completion Dec 2, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This open-label, randomized, three-period crossover, 8-hour hyperinsulinemic-euglycemic clamp study will compare the pharmacokinetic and pharmacodynamic profiles of THDB0206 after single subcutaneous administration at different injection sites in healthy Chinese adults.

Conditions

  • Healthy Participants

Interventions

  • THDB0206 injection-Upper armDrug

    Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the upper arm.

  • THDB0206 Injection-AbdomenDrug

    Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the abdomen.

  • THDB0206 Injection-ThighDrug

    Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the thigh.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCLisp(0-inf)Time frame: From 0 to 8 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.